Posted on

New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

Loading

DECEMBER, 21, 2022

ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies

ISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need for Biopsies and Hospital Visits

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio. Read the complete press release on CareDx.com.

Loading
Posted on

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Loading

Study Reaffirms Benefits of AlloMap, the Industry’s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.2 The study also highlights that the associated AlloMap blood test draw can be performed in the patient’s home to help reduce the risk of exposure to infection. Read the complete press release on CareDx.com.

Loading